The Vaccine Group is using recombinant viral vector technology to develop new animal vaccines and biotherapeutics for use in livestock and companion animals:

• Diseases caused by agents such as Streptococcus suis, an emerging zoonotic disease in pigs that can cause meningitis and other severe symptoms in humans, bovine tuberculosis, porcine reproductive & respiratory syndrome, porcine circovirus, bovine respiratory syncytial virus, lumpy skin disease, ovine enzootic abortion and African swine fever which have a high impact on production of economically important livestock;
• Diseases caused by agents such as leishmaniasis, equine influenza and feline immunodeficiency;
• Diseases of ageing and chronic health conditions in pet animals.

The company now has a pipeline of 17 vaccine and therapeutic candidates designed to combat diseases that cause serious economic harm to the livestock industry or tackle unmet needs in the companion animal sector. You can learn more about the pipeline here.

TVG was founded in 2017 to develop and commercialise the work of Dr Michael Jarvis, Associate Professor of Virology and Immunology at the University of Plymouth’s School of Biomedical Sciences, and the company’s Chief Scientific Officer. To date, work has been funded by a mix of public grants and equity investment. Its business model is to develop vaccines to proof of concept stage and then license them to manufacturers for commercial exploitation.